Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on 8/16/18 positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.